Business Acquisitions (Tables)

12 Months Ended

Dec. 31, 2022

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as a result of the In2Bones and Biorez Acquisitions that were accounted for as business combinations. The assessment of fair value is based on preliminary valuations and estimates that were available to management at the time the consolidated financial statements were prepared. Accordingly, the allocation of purchase price is preliminary and therefore subject to adjustment during the measurement adjustment period.

	In2Bones		Biorez
Cash	$	445	$	754
Accounts receivable, net	5,036		318
Inventories	24,247		61
Prepaid expenses and other current assets	1,490		118
Current assets	31,218		1,251
Goodwill	139,128		60,034
Developed technology	37,300		176,300
Distributor relationships	27,600		—
Trademarks and tradenames	—		1,600
Other long-term assets	2,875		112
Total assets acquired	$	238,121	$	239,297
Current liabilities assumed	6,332		1,441
Deferred income taxes	16,738		37,801
Other long-term liabilities	466		—
Total liabilities assumed	$	23,536	$	39,242
Net assets acquired	$	214,585	$	200,055

Fair Value Measurement Inputs and Valuation Techniques

The recurring Level 3 fair value measurements of contingent consideration for which the liability was recorded at the acquisition date include the following significant unobservable inputs:

	Assumptions
Unobservable Input	In2Bones	Biorez
Discount rate	5.67%	10.34%
Revenue volatility	12.75%	18.87%
Projected year of payment	2023-2026	2023-2026